| Singular Genomics Announces Closing of Acquisition by Deerfield Management |
SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P. |
globenewswire.com |
2025-02-21 11:56:00 |
Czytaj oryginał (ang.) |
| Investors With Losses Are Invited To Join The Schall Law Firm In An Investigation Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 30, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-30 13:00:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 29, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-29 13:00:00 |
Czytaj oryginał (ang.) |
| OMIC Investors Have the Opportunity to Join Investigation of Singular Genomics Systems, Inc. with the Schall Law Firm |
LOS ANGELES , Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ: OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
prnewswire.com |
2025-01-28 05:40:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-27 13:45:00 |
Czytaj oryginał (ang.) |
| Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 26, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-26 13:30:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-25 13:30:00 |
Czytaj oryginał (ang.) |
| Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 24, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-24 13:15:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 23, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-23 13:30:00 |
Czytaj oryginał (ang.) |
| Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-22 13:00:00 |
Czytaj oryginał (ang.) |
| SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Singular Genomics Systems, Inc. (NasdaqCM: OMIC) to an affiliate of Deerfield Management Company, L.P. Under the terms of the proposed transaction, shareholders of Singular will receive $20.00 in cash for each share of Singular that they own. KSF is seeking to determine whether this consideration and the proce. |
businesswire.com |
2025-01-21 18:57:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-21 13:00:00 |
Czytaj oryginał (ang.) |
| Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-20 13:00:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-19 13:15:00 |
Czytaj oryginał (ang.) |
| Investors With Losses Are Invited To Join The Schall Law Firm In An Inquiry Into Singular Genomics Systems, Inc. For Securities Fraud |
LOS ANGELES, CA / ACCESS Newswire / January 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-18 13:30:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Urges Affected Shareholders To Reach Out |
LOS ANGELES, CA / ACCESS Newswire / January 17, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Singular Genomics Systems, Inc. ("Singular Genomics" or "the Company") (NASDAQ:OMIC) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Singular Genomics board breached its fiduciary duties to shareholders. |
accessnewswire.com |
2025-01-17 20:30:00 |
Czytaj oryginał (ang.) |
| OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Singular Genomics Systems, Inc. (NASDAQ: OMIC) to an affiliate of Deerfield Management Company, L.P. for $20.00 per share is fair to Singular Genomics shareholders. Halper Sadeh encourages Singular Genomics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpers. |
businesswire.com |
2025-01-15 13:18:00 |
Czytaj oryginał (ang.) |
| SINGULAR GENOMICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Singular Genomics Systems, Inc. - OMIC |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Singular Genomics Systems, Inc. (NasdaqCM: OMIC) to an affiliate of Deerfield Management Company, L.P. Under the terms of the proposed transaction, shareholders of Singular will receive $20.00 in cash for each share of Singular that they own. KSF is seeking to determine whether this consideration and the proce. |
businesswire.com |
2025-01-06 20:17:00 |
Czytaj oryginał (ang.) |
| OMIC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Singular Genomics Systems, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Singular Genomics Systems, Inc. (NASDAQ: OMIC) to an affiliate of Deerfield Management Company, L.P. for $20.00 per share is fair to Singular Genomics shareholders. Halper Sadeh encourages Singular Genomics shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpers. |
businesswire.com |
2024-12-23 12:51:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: Ademi LLP Investigates Whether Singular Genomics Systems, Inc. is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Singular Genomics (Nasdaq: OMIC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Deerfield. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Singular Genomics shareholders will receive $20.00 per share. Singular Genomics insiders will re. |
businesswire.com |
2024-12-23 12:16:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share |
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC) (“Singular Genomics” or the “Company”), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. |
globenewswire.com |
2024-12-23 10:30:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital |
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received an unsolicited non-binding proposal from Concentra Biosciences, LLC (“Concentra”) to acquire all of the Company's outstanding shares of common stock for $12.00 per share in cash. As alternative consideration, Concentra stated that it would consider, assuming it receives sufficient interest from existing stockholders, inviting interested stockholders to elect to continue to participate in any future value realized from the Company's ongoing business by receiving a contingent value right in lieu of receiving $12.00 per share in cash. |
globenewswire.com |
2024-09-19 21:24:00 |
Czytaj oryginał (ang.) |
| $1.8M Bet On Singular Genomics? Check Out These 3 Stocks Executives Are Buying |
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades. |
benzinga.com |
2024-09-19 13:53:57 |
Czytaj oryginał (ang.) |
| Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield |
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today that it has received a non-binding proposal from Deerfield Management Company, L.P. and certain affiliated funds (collectively, “Deerfield”), to acquire all of the Company's outstanding shares of common stock that are not already owned by Deerfield for $10.00 per share in cash. Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company. |
globenewswire.com |
2024-09-12 20:31:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript |
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Daniel Brennan - TD Cowen Matthew Sykes - Goldman Sachs Operator Greeting. Welcome to the Singular Genomics Second Quarter and Business Update Call. |
seekingalpha.com |
2024-08-14 01:44:03 |
Czytaj oryginał (ang.) |
| Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024 |
SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-07-30 21:05:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement |
SAN DIEGO, July 15, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it received formal notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. |
globenewswire.com |
2024-07-15 20:05:00 |
Czytaj oryginał (ang.) |
| Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday |
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: |
benzinga.com |
2024-06-24 07:32:55 |
Czytaj oryginał (ang.) |
| Singular Genomics Announces 1-for-30 Reverse Stock Split |
SAN DIEGO, June 21, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that on June 26, 2024, effective at 12:01 a.m. Eastern Time, it will effectuate a 1-for-30 reverse split of its common stock. The Company's common stock will begin trading on a split-adjusted basis when the market opens on June 26, 2024 under its current trading symbol “OMIC”. The CUSIP number of the Company's common stock following the reverse stock split will be 82933R 308. |
globenewswire.com |
2024-06-21 20:05:00 |
Czytaj oryginał (ang.) |
| Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference |
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida. |
globenewswire.com |
2024-05-29 20:05:00 |
Czytaj oryginał (ang.) |
| Lab Instrument Industry Update - New Commercial Entrants |
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry high risks. Cytek stands out as the best opportunity in the sector due to strong growth and manageable losses. |
seekingalpha.com |
2024-05-23 13:17:40 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. (OMIC) Q1 2024 Earnings Call Transcript |
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2024 Results Conference Call May 14, 2024 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good afternoon, everyone, and welcome to the Singular Genomics Systems Inc. First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-15 00:04:08 |
Czytaj oryginał (ang.) |
| Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results |
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024. |
globenewswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript |
Singular Genomics Systems, Inc. (OMIC) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-03-18 21:07:03 |
Czytaj oryginał (ang.) |
| Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results |
SAN DIEGO, March 18, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the fourth quarter and full year ended December 31, 2023. |
globenewswire.com |
2024-03-18 18:05:00 |
Czytaj oryginał (ang.) |
| Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 |
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
globenewswire.com |
2024-03-04 18:05:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Showcases New G4X™ Spatial Sequencer at AGBT and Announces Significant Advances in Throughput, Quality, and Usability for G4® Sequencing Platform |
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced groundbreaking new products and capabilities at the Advances of Genome Biology and Technology (AGBT) conference in Orlando, Florida. |
globenewswire.com |
2024-02-05 12:55:00 |
Czytaj oryginał (ang.) |
| Singular Genomics Unveils G4X™ Spatial Sequencer, Transforming the Landscape of In Situ Multiomic Analysis |
SAN DIEGO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today unveiled the G4X™ Spatial Sequencer. The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. The G4X will share the same platform as the existing G4® sequencer and is expected to be the industry's first dual-purpose instrument offering both traditional NGS and tissue-based spatial sequencing capabilities. With the addition of high-throughput multiomics and novel Direct-Seq technology to its portfolio with the G4X, Singular is positioned to become the only company worldwide to offer in situ spatial sequencing of tissues and NGS on the same instrument. |
globenewswire.com |
2024-02-05 12:54:00 |
Czytaj oryginał (ang.) |